Effects of meteorology and human-mobility on UK's air quality during COVID-19

Efforts to prevent the spread of the coronavirus disease 2019 (COVID‐19) pandemic have had profound positive and negative impacts on social and environmental indicators worldwide. For the first time, a scenario of a partial economic shutdown could be measured, and large tech companies published wide‐coverage mobility reports to quantify the impacts on social change with anonymized location data. During the COVID‐19 pandemic, the UK government has employed some of the strictest lockdown periods in the world, causing an immediate halt to travel and business activities. From these repeated lockdown periods, we have gained a snapshot of life without excessive human‐made pollution; this has allowed us to interrogate the interaction between meteorology and air quality with minimal anthropogenic input. Our findings show a warmer 2020 increased the UK's ozone levels by 9%, while reductions in human‐mobility reduced UK‐wide nitrogen dioxide levels by 25% in 2020, which have remained low during the first months of 2021 despite curtailing/ending of restrictions; and a decrease in particulate matter created by meteorological and human drivers. Regionally, London records the highest NO(2) and O(3) changes, −31% and 35%, respectively, linked to mobility reductions and meteorology

Anomalous diffusion in a bench-scale pulsed fluidized bed

We present our analysis on micro-rheology of a bench-scale pulsed fluidized bed, which represents a weakly confined system. Non-linear gas-particle and particle-particle interactions resulting from pulsed flow are associated with harmonic and sub-harmonic modes. While periodic structured bubble patterns are observed at the meso-scale, particle-scale measurements reveal anomolous diffusion in the driven granular medium. We use single-particle tracks to analyze ergodicity and ageing properties at two pulsing frequencies having remarkably different meso-scale features. The scaling of ensemble-averaged mean squared displacement is not unique. The distribution of time-averaged mean squared displacements is non-Gaussian, asymmetric and has a finite trivial contribution from particles in crowded quasi-static surroundings. Results indicate weak ergodicity breaking which along with ageing characterize the non-stationary and out-of-equilibrium dynamics.Comment: 18 pages, 9 figure

Proper orthogonal decomposition of ice velocity identifies drivers of flow variability at Sermeq Kujalleq (Jakobshavn Isbr AE)

Abstract. The increasing volume and spatio-temporal resolution of satellite-derived ice velocity data has created new exploratory opportunities for the quantitative analysis of glacier dynamics. One potential technique, Proper Orthogonal Decomposition (POD), also known as Empirical Orthogonal Functions, has proven to be a powerful and flexible technique for revealing coherent structures in a wide variety of environmental flows. In this study we investigate the applicability of POD to an openly available TanDEM-X/TerraSAR-X derived ice velocity dataset from Sermeq Kujalleq (Jakobshavn Isbræ), Greenland. We find three dominant modes with annual periodicity that we argue are explained by glaciological processes. Mode 1 is interpreted as relating to the stress-reconfiguration at the glacier terminus, known to be an important control on the glacier’s dynamics. Modes 2 and 3 together relate to the development of the spatially heterogenous glacier hydrological system and are primarily driven by the pressurisation and efficiency of the subglacial hydrological system. During the melt season, variations in the velocity shown in Modes 2 and 3 are explained by the drainage of nearby supraglacial melt ponds, as identified with a Google Earth Engine MODIS dynamic thresholding technique. By isolating statistical structures within velocity datasets, and through their comparison to glaciological theory and complementary datasets POD indicates which glaciological processes are responsible for the changing bulk velocity signal, as observed from space. With the proliferation of optical and radar derived velocity products (e.g. MEaSUREs/ESA CCI/PROMICE) we suggest POD, and potentially other modal decomposition techniques, will become increasingly useful in future studies of ice dynamics. </jats:p

Local CpG density affects the trajectory and variance of age-associated DNA methylation changes

Acknowledgements We thank Riccardo Marioni, Chris Haley, Ailith Ewing, David Porteous, Chris Ponting, Rob Illingworth, Tamir Chandra, Sara Hagg, Yunzhang Wang, Chantriolnt-Andreas Kapourani, Nick Gilbert, Hannes Becher and members of the Sproul lab for helpful discussions about the study and the manuscript. This work has made use of the resources provided by the University of Edinburgh digital research services and the MRC IGC compute cluster. We are grateful to all the families who took part in the Generation Scotland study along with the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the entire Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants, and nurses. Peer review information Anahita Bishop and Kevin Pang were the primary editors of this article and managed its editorial process and peer review in collaboration with the rest of the editorial team. Review history The review history is available as Additional file 3. Funding DS is a Cancer Research UK Career Development fellow (reference C47648/A20837), and work in his laboratory is also supported by an MRC university grant to the MRC Human Genetics Unit. LK is a cross-disciplinary postdoctoral fellow supported by funding from the University of Edinburgh and Medical Research Council (MC_UU_00009/2). S.R.C. and I.J.D. were supported by a National Institutes of Health (NIH) research grant R01AG054628, and S.R.C is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (221890/Z/20/Z). AMM is supported by the Wellcome Trust (104036/Z/14/Z, 216767/Z/19/Z, 220857/Z/20/Z) and UKRI MRC (MC_PC_17209, MR/S035818/1). PMV acknowledges support from the Australian National Health and Medical Research Council (1113400) and the Australian Research Council (FL180100072). DMH is supported by a Sir Henry Wellcome Postdoctoral Fellowship (Reference 213674/Z/18/Z). We thank the LBC1936 participants and team members who contributed to the study. Further study information can be found at https://www.ed.ac.uk/lothian-birth-cohorts. The LBC1936 is supported by a jointly funded grant from the BBSRC and ESRC (BB/W008793/1), and also by Age UK (Disconnected Mind project), the Medical Research Council (G0701120, G1001245, MR/M013111/1, MR/R024065/1), and the University of Edinburgh. Genotyping of LBC1936 was funded by the BBSRC (BB/F019394/1), and methylation typing of LBC1936 was supported by Centre for Cognitive Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, The Wellcome Trust Institutional Strategic Support Fund, The University of Edinburgh, and The University of Queensland. Work on Generation Scotland was supported by a Wellcome Strategic Award “STratifying Resilience and Depression Longitudinally” (STRADL; 104036/Z/14/Z) to AMM, KLE, and others, and an MRC Mental Health Data Pathfinder Grant (MC_PC_17209) to AMM. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). DNA methylation profiling and analysis of the GS:SFHS samples was supported by Wellcome Investigator Award 220857/Z/20/Z and Grant 104036/Z/14/Z (PI: AM McIntosh) and through funding from NARSAD (Ref: 27404; awardee: Dr DM Howard) and the Royal College of Physicians of Edinburgh (Sim Fellowship; Awardee: Dr HC Whalley).Peer reviewedPublisher PD

Age-related clonal haematopoiesis is associated with increased epigenetic age

Age-related clonal haemopoiesis (ARCH) in healthy individuals was initially observed through an increased skewing in X-chromosome inactivation [1]. More recently, several groups reported that ARCH is driven by somatic mutations [2], with the most prevalent ARCH mutations being in the DNMT3A and TET2 genes, previously described as drivers of myeloid malignancies. ARCH is associated with an increased risk for haematological cancers [2]. ARCH also confers an increased risk for non-haematological diseases, such as cardiovascular disease, atherosclerosis, and chronic ischemic heart failure, for which age is a main risk factor 3, 4. Whether ARCH is linked to accelerated ageing has remained unexplored. The most accurate and commonly used tools to measure age acceleration are epigenetic clocks: they are based on age-related methylation differences at specific CpG sites [5]. Deviations from chronological age towards an increased epigenetic age have been associated with increased risk of earlier mortality and age-related morbidities 5, 6. Here we present evidence of accelerated epigenetic age in individuals with ARCH

Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial

Background: The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7% efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-blinded, placebo-controlled trial in the United Kingdom. The protocol was amended to include a blinded crossover. Data to the end of the placebo-controlled phase are reported. Methods: Adults aged 18–84 years received 2 doses of NVX-CoV2373 or placebo (1:1) and were monitored for virologically confirmed mild, moderate, or severe COVID-19 (onset from 7 days after second vaccination). Participants who developed immunoglobulin G (IgG) against nucleocapsid protein but did not show symptomatic COVID-19 were considered asymptomatic. Secondary outcomes included anti-spike (S) IgG responses, wild-type virus neutralization, and T-cell responses. Results: Of 15 185 participants, 13 989 remained in the per-protocol efficacy population (6989 NVX-CoV2373, 7000 placebo). At a maximum of 7.5 months (median, 4.5) postvaccination, there were 24 cases of COVID-19 among NVX-CoV2373 recipients and 134 cases among placebo recipients, a vaccine efficacy of 82.7% (95% confidence interval [CI], 73.3%–88.8%). Vaccine efficacy was 100% (95% CI, 17.9%–100.0%) against severe disease and 76.3% (95% CI, 57.4%–86.8%) against asymptomatic disease. High anti-S and neutralization responses to vaccination were evident, together with S-protein–specific induction of interferon-γ secretion in peripheral blood T cells. Incidence of serious adverse events and adverse events of special interest were similar between groups. Conclusions: A 2-dose regimen of NVX-CoV2373 conferred a high level of ongoing protection against asymptomatic, symptomatic, and severe COVID-19 through >6 months postvaccination. A gradual decrease of protection suggests that a booster may be indicated. Clinical Trials Registration: EudraCT, 2020-004123-16

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

Acknowledgements The study and article were funded by Novavax. We would like to thank all the study participants for their commitment to this study. We also acknowledge the investigators and their study teams for their hard work and dedication. In addition, we would like to thank the National Institute for Health Research, representatives from the Department of Health and Social Care laboratories and NHS Digital and the members of the UK Vaccine Task Force. Editorial support was provided by Kelly Cameron of Ashfield MedComms, an Inizio company Funding This work was funded by Novavax, and the sponsor had primary responsibility for study design, study vaccines, protocol development, study monitoring, data management, and statistical analyses. All authors reviewed and approved the manuscript before submission. LF reports a position as a prior full-time employee, now contractor to Novavax re-imbursed hourly for work performed on this study and in analyses and drafting this report. IC reports providing medical writing support for this work as an employee of NovavaxPeer reviewedPublisher PD